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Change – the one thing you can count on …
A recent paper by Meyer and colleagues reminds us of 
this statement, and suggests we may have forgotten 
something in our rush to exploit the ﬁ  rst set of breast 
cancer stem cell markers identiﬁ  ed [1]. Namely, a full 
analysis of the developmental and tumor-initiating 
potential of the CD44pos;CD24pos breast cancer cell.
In 2003, two cell surface markers – CD44high and 
CD24low/– – were associated with breast cancer stem cells 
[2]. In xenograft transplantation studies, this cell popu-
lation regenerated tumors at high frequency whereas 
other cell populations were depleted for this function. 
Subsequent work in breast cancer cell lines showed that 
CD44high;CD24low/– cells were present in culture, and were 
also tumorigenic upon transplantation, with CD24 posi-
tivity being associated with decreased invasiveness (for 
example [3,4]). Naturally, this work set oﬀ   a ﬂ  urry  of 
activity to characterize the CD44high;CD24low/– population 
molecularly relative to other populations present in 
tumors [5-8], and to evaluate their response to treatment 
(for example [9,10]).
In the wake of this ﬂ  urry of activity, it appears we may 
have forgotten something – to determine the full 
develop  mental and tumor-initiating potential of the 
CD44pos;CD24pos cell. Th  e recent paper by Meyer and 
colleagues conﬁ   rms that CD44pos;CD24low/–  cells in a 
number of cell lines can give rise to CD44pos;CD24pos cells, 
and can yield total populations characteristic of the 
parental line [1]. Th  is  ﬁ  nding is not surprising, and in fact 
is as expected for a cancer stem cell. Using ﬂ  ow cyto-
metry and single cell culture, however, these authors 
went on to show that the converse can also occur – 
CD44pos;CD24pos cells can give rise to their 
CD44pos;CD24low/–  counterparts, and are subse  quently 
also capable of initiating tumors as xenografts with high 
eﬃ   ciency. Further, their paper shows that the develop-
mental potential for either CD44pos cell population to 
regenerate the other was dependent on activin/nodal 
signaling.
While the analysis was limited to established cell lines, 
what these data imply is that the status of CD24 is 
dynamically regulated in a developmental context, and 
suggests that the CD24 status may ultimately be 
immaterial as to whether or not the CD44pos population 
is capable of initiating tumors. In addition, these data 
also imply that current eﬀ  orts by many groups to develop 
agents that speciﬁ   cally target the CD44high;CD24low/–
population may be destined to fail unless activin/nodal 
signaling is also prevented.
Aside from the potential implications on translational 
research, if conﬁ   rmed clinically, these results beg the 
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initiating cells as static entities given the fact that the 
plasticity of normal mammary epithelial cells is, in some 
circles, the stuﬀ   of legends [11].
In the normal gland, plasticity comes in a couple of 
diﬀ  erent forms. First, cellular plasticity – the character of 
a given cell can change dramatically over the course of 
gland development (for example, virgin ducts versus 
preg  nancy, or lactation versus involution), and in 
response to treatment with a bioactive agent (for example, 
hormones, growth factors). Similarly, there is develop-
mental plasticity – the observation that subsets of 
mammary epithelial cells retain the ability to give rise to 
multiple cell types at deﬁ   ned phases of development, 
although they do not express this ability until needed.
As an example of cellular plasticity, cells already 
present within the duct of a virgin mouse (and probably 
of human) in early pregnancy are induced to proliferate 
and ultimately give rise to alveolar structures capable of 
producing copious amounts of milk. At least some of 
these cells can be parity identiﬁ  ed after the fact using 
elegant genetic tagging methods sensitive to at least some 
degree of alveolar diﬀ   erentiation. Transplantation of 
these tagged populations suggests that a subset of 
diﬀ   erentiated alveolar epithelial cells survive the 
involution process after weaning and retain a high degree 
of regenerative and multilineage diﬀ  erentiation capacity 
upon transplantation [12,13].
With respect to developmental plasticity, we know that 
regenerative stem cells are present throughout the 
mature mammary gland in the virgin animal. Small 
fragments of duct derived from any portion of the gland 
are capable of regenerating a functional mammary gland 
when transplanted into a mammary fat pad lacking its 
endogenous epithelium [14,15]. If a fragment of duct is 
transplanted into an intact mammary fat pad already 
containing epithelium, however, it does not regenerate. 
Further, actively growing terminal end buds in the 
mammary gland, which by deﬁ  nition contain regenera-
tive stem cells, do not run into each other and, in fact, are 
regularly spaced from one another throughout the 
mammary gland [14].
Th   e inference is that regenerative stem cells resident in 
the mature duct are not generally actively engaged in 
stem cell behaviors, and are strongly growth-inhibited by 
the presence of neighboring normal mammary epithe-
lium. Th  e behavior of regenerative stem cells is thus 
entirely dependent on the environment in which it ﬁ  nds 
itself. Further, there is high probability that gene expres-
sion in an actively regenerating stem cell is probably quite 
diﬀ  erent from gene expression in a quiescent stem cell.
If normal mammary epithelial cells are plastic, why 
should we not expect malignant epithelium to share this 
characteristic?
We are clearly in desperate need of new, rigorously 
validated, markers of normal and malignant stem cells. 
Perhaps most importantly, however, we need to ensure 
that newly emerging therapeutics intended to target 
tumor-initiating cancer stem cells are evaluated carefully 
for their ability to eliminate all sources of such cells 
completely, lest they ﬁ   nd a way to express the 
developmental plasticity with which they appear to be 
endowed.
Change – count on it.
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